MDM2 SNP309 does not associate with elevated MDM2 protein
expression or breast cancer risk

J 2008

MDM2 SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk

KREKÁČ, Daniel, Kristýna BROŽKOVÁ, Dana KNOFLÍČKOVÁ, Roman HRSTKA, Petr MÜLLER et. al.

Základní údaje

Originální název

MDM2 SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk

Autoři

KREKÁČ, Daniel (703 Slovensko), Kristýna BROŽKOVÁ (203 Česká republika, garant), Dana KNOFLÍČKOVÁ (203 Česká republika), Roman HRSTKA (203 Česká republika), Petr MÜLLER (203 Česká republika), Rudolf NENUTIL (203 Česká republika) a Bořivoj VOJTĚŠEK (203 Česká republika)

Vydání

Oncology, Basel, S. Karger AG, 2008, 0030-2414

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.336

Kód RIV

RIV/00216224:14310/08:00039782

Organizační jednotka

Přírodovědecká fakulta

UT WoS

000256752300013

Klíčová slova anglicky

MDM2; SNP309; p53

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 3. 2010 15:54, Mgr. Kristýna Hrazdilová, Ph.D.

Anotace

V originále

SNP309 polymorphism (T-G) at the promoter region of MDM2 has been reported to cause increased binding affinity of transcriptional activator Sp1 followed by increased MDM2 both in mRNA and protein level. This model was proposed in vitro in the small panel of cell lines that indicated an on average 8-fold higher level of MDM2 mRNA in cells bearing the GG genotype. No significant difference was observed in the G allele incidence in breast cancer specimens compared to 149 noncancer controls. Furthermore, no statistically significant association of the G allele frequencies and p53 and MDM2 protein expression levels was observed. Our data clearly show neither association between SNP309 and cancer risk, nor the responsibility of G allele for increased MDM2 or decreased of p53 protein levels in human primary breast tumors.

Citovat

KREKÁČ, Daniel, Kristýna BROŽKOVÁ, Dana KNOFLÍČKOVÁ, Roman HRSTKA, Petr MÜLLER, Rudolf NENUTIL a Bořivoj VOJTĚŠEK. MDM2 SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology. Basel: S. Karger AG, 2008, roč. 74, 1-2, s. 84-87. ISSN 0030-2414.

@article{878227,
   author = {Krekáč, Daniel and Brožková, Kristýna and Knoflíčková, Dana and Hrstka, Roman and Müller, Petr and Nenutil, Rudolf and Vojtěšek, Bořivoj},
   article_location = {Basel},
   article_number = {1-2},
   keywords = {MDM2; SNP309; p53},
   language = {eng},
   issn = {0030-2414},
   journal = {Oncology},
   title = {MDM2 SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk},
   volume = {74},
   year = {2008}
}

TY  - JOUR
ID  - 878227
AU  - Krekáč, Daniel - Brožková, Kristýna - Knoflíčková, Dana - Hrstka, Roman - Müller, Petr - Nenutil, Rudolf - Vojtěšek, Bořivoj
PY  - 2008
TI  - MDM2 SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk
JF  - Oncology
VL  - 74
IS  - 1-2
SP  - 84-87
EP  - 84-87
PB  - S. Karger AG
SN  - 00302414
KW  - MDM2
KW  - SNP309
KW  - p53
N2  - SNP309 polymorphism (T-G) at the promoter region of MDM2 has been reported to cause increased binding affinity of transcriptional activator Sp1 followed by increased MDM2 both in mRNA and protein level. This model was proposed in vitro in the small panel of cell lines that indicated an on average 8-fold higher level of MDM2 mRNA in cells bearing the GG genotype. No significant difference was observed in the G allele incidence in breast cancer specimens compared to 149 noncancer controls. Furthermore, no statistically significant association of the G allele frequencies and p53 and MDM2 protein expression levels was observed. Our data clearly show neither association between SNP309 and cancer risk, nor the responsibility of G allele for increased MDM2 or decreased of p53 protein levels in human primary breast tumors.
ER  -

KREKÁČ, Daniel, Kristýna BROŽKOVÁ, Dana KNOFLÍČKOVÁ, Roman HRSTKA, Petr MÜLLER, Rudolf NENUTIL a Bořivoj VOJTĚŠEK. MDM2 SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. \textit{Oncology}. Basel: S. Karger AG, 2008, roč.~74, 1-2, s.~84-87. ISSN~0030-2414.

Podrobný výpis o publikaci